Asset Details
Do you wish to reserve the book?
Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease
Do you wish to request the book?
Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease
2013
Overview
Development of steroid dependency in patients with nephrotic syndrome may require a long-term multi-drug therapy at risk of drug toxicity and renal failure. Rituximab treatment reduces the steroid dosage and the need for immunosuppressive therapy in pediatric patients. Here we retrospectively analyze the efficacy and safety of rituximab in adult patients with steroid-dependent minimal change disease. To do this, we analyzed the outcome of all adult patients treated with rituximab for steroid-dependent minimal change nephrotic syndrome over a mean follow-up of 29.5 months (range 5.1–82 months). Seventeen patients with steroid-dependent or frequently relapsing minimal change nephrotic syndrome, unresponsive to several immunosuppressive medications, were treated with rituximab. Eleven patients had no relapses after rituximab infusion (mean follow-up 26.7 months, range 5.1–82 months) and nine of them were able to come off all other immunosuppressive drugs and steroids during follow-up. Six patients relapsed at least once after a mean time of 11.9 months (mean follow-up 34.5 months, range 16.9–50.1 months), but their immunosuppressive drug treatment could be stopped or markedly reduced during this time. No adverse events were recorded. Thus, rituximab is efficient and safe in adult patients suffering from severe steroid-dependent minimal change disease. Prospective randomized trials are needed to confirm this study.
Publisher
Elsevier Inc,Elsevier Limited,Nature Publishing Group
Subject
/ Adult
/ Aged
/ Antibodies, Monoclonal, Murine-Derived
/ Antibodies, Monoclonal, Murine-Derived - adverse effects
/ Antibodies, Monoclonal, Murine-Derived - therapeutic use
/ Biochemistry, Molecular Biology
/ Female
/ Genomics
/ Humans
/ Immunosuppressive Agents - therapeutic use
/ Male
/ Nephrosis, Lipoid - drug therapy
